Treatment outcomes of primary central nervous system lymphoma: Multi-center retrospective study.
- Author:
Joon Ho MOON
1
;
Dong Hwan KIM
;
Byung Min AHN
;
Shi Nae KIM
;
Seok Bong JEON
;
Jin Ho BAEK
;
Jong Gwang KIM
;
Sang Kyun SOHN
;
Kyu Bo LEE
;
Jeong Hyun HWANG
;
Sung Kyoo HWANG
;
Je Jung LEE
;
Yeo Kyeoung KIM
;
Ik Joo CHUNG
;
Hyeoung Joon KIM
;
Deok Hwan YANG
;
Shin JUNG
;
Young Rok DO
;
Ki Young KWON
;
Hong Suk SONG
;
Won Sup LEE
Author Information
1. Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea. sksohn@knu.ac.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Lymphoma;
Central Nervous System;
CHOP;
High-dose methotrexate;
Radiotherapy
- MeSH:
Central Nervous System*;
Disease-Free Survival;
Drug Therapy;
Humans;
Leukoencephalopathies;
Lymphoma*;
Lymphoma, B-Cell;
Lymphoma, T-Cell, Peripheral;
Methotrexate;
Prognosis;
Radiotherapy;
Retrospective Studies*;
Survival Rate
- From:Korean Journal of Medicine
2006;71(6):654-661
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: A primary central nervous system lymphoma (PCNSL) is a rare neoplasm with a poor prognosis. The treatment of PCNSL involves a combination of chemotherapy, intrathecal chemotherapy and radiotherapy. This study retrospectively evaluated the treatment outcomes and prognostic factors of Korean patients with PCNSL. METHODS: Between 1995 and 2003, 58 patients diagnosed with PCNSL from the multi-center hospitals were enrolled in this study. Among 56 patients who had received treatment, 16 patients were treated with radiotherapy alone, while 40 patients were treated with combined chemotherapy (CHOP; 9 cases, high-dose methotrexate; 31 cases) and radiotherapy. RESULTS: The median age of the patients was 58 years (range, 19-76). A diffuse large B-cell lymphoma was diagnosed in 56 cases (96.6%), while a peripheral T-cell lymphoma was diagnosed in 2 cases. Of the 47 patients who could be assessed for their response after treatment, a CR and PR was observed in 32 (68%) and 11 patients (23%), respectively, giving an overall response rate of 91% (95% CI, 82~100%). The estimated 3-year overall survival rate for all the patients was 67+/-7.9% and the 3-year disease free survival rate was 53+/-8.3%. The overall survival of the high-dose methotrexate group was superior to that of the CHOP group (77+/-10% versus 47+/-19%, p=0.05). Leukoencephalopathy was observed as a late complication in 9 patients (21%). No significant prognostic factors affecting survival were found by univariate analysis. CONCLUSIONS: Approximately half of the patients could have long-term survival after treatment in this study. High-dose methotrexate containing chemotherapy followed by radiotherapy was found to be an effective treatment.
